PRLD
Price:
$4.32
Market Cap:
$178.38M
Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on identifying and developing innovative, targeted cancer treatments for patient populations with unmet medical needs. Its pipeline includes PRT543, currently undergoing Phase 1 clinical evaluation for certain solid tumors and myeloid malignancies. Another asset, PRT811, is also in Phase 1 trials, targeting various solid tumors, notably glioblastoma multiforme. The company is additionally progressing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a powerful and highly kinome-selective CDK9 inhibitor; PRT-SCA2, which is in preclinical development for several genomically selecte...[Read more]
Industry
Biotechnology
IPO Date
2020-09-25
Stock Exchange
NASDAQ
Ticker
PRLD
According to Prelude Therapeutics Incorporated’s latest financial reports and current stock price. The company's current PE Ratio is -4.32. This represents a change of 53.69% compared to the average of -2.81 of the last 4 quarters.
The mean historical PE Ratio of Prelude Therapeutics Incorporated over the last ten years is -12.72. The current -4.32 PE Ratio has changed 3.29% with respect to the historical average. Over the past ten years (40 quarters), PRLD's PE Ratio was at its highest in in the March 2025 quarter at -0.46. The PE Ratio was at its lowest in in the December 2020 quarter at -35.07.
Average
-12.72
Median
-2.74
Minimum
-55.04
Maximum
-0.76
Discovering the peaks and valleys of Prelude Therapeutics Incorporated PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 995.29%
Maximum Annual PE Ratio = -0.76
Minimum Annual Increase = -90.29%
Minimum Annual PE Ratio = -55.04
| Year | PE Ratio | Change |
|---|---|---|
| 2025 | -2.25 | 197.38% |
| 2024 | -0.76 | -64.24% |
| 2023 | -2.11 | -20.56% |
| 2022 | -2.66 | -50.20% |
| 2021 | -5.34 | -90.29% |
| 2020 | -55.04 | 78.56% |
| 2019 | -30.82 | 995.29% |
The current PE Ratio of Prelude Therapeutics Incorporated (PRLD) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages
3-year avg
-1.71
5-year avg
-2.62
10-year avg
-12.72
Prelude Therapeutics Incorporated’s PE Ratio is less than Pyxis Oncology, Inc. (-1.55), less than Orchestra BioMed Holdings, Inc. (-2.81), greater than Enanta Pharmaceuticals, Inc. (-4.62), less than Caribou Biosciences, Inc. (-1.15), less than Inventiva S.A. (-1.61), less than Tenaya Therapeutics, Inc. (-1.55), less than Avalo Therapeutics, Inc. (-2.52), greater than Eupraxia Pharmaceuticals Inc. (-6.09), less than Immuneering Corporation (-3.77), less than Foghorn Therapeutics Inc. (-3.55),
| Company | PE Ratio | Market cap |
|---|---|---|
| -1.55 | $128.61M | |
| -2.81 | $238.92M | |
| -4.62 | $293.92M | |
| -1.15 | $162.66M | |
| -1.61 | $185.58M | |
| -1.55 | $121.72M | |
| -2.52 | $166.02M | |
| -6.09 | $216.95M | |
| -3.77 | $160.09M | |
| -3.55 | $243.66M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Prelude Therapeutics Incorporated using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Prelude Therapeutics Incorporated or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Prelude Therapeutics Incorporated's PE Ratio?
How is the PE Ratio calculated for Prelude Therapeutics Incorporated (PRLD)?
What is the highest PE Ratio for Prelude Therapeutics Incorporated (PRLD)?
What is the 3-year average PE Ratio for Prelude Therapeutics Incorporated (PRLD)?
What is the 5-year average PE Ratio for Prelude Therapeutics Incorporated (PRLD)?
How does the current PE Ratio for Prelude Therapeutics Incorporated (PRLD) compare to its historical average?